PetIQ Inc (PETQ) Expected to Post Quarterly Sales of $139.03 Million
Brokerages forecast that PetIQ Inc (NASDAQ:PETQ) will post sales of $139.03 million for the current fiscal quarter, according to Zacks Investment Research. Five analysts have issued estimates for PetIQ’s earnings, with the lowest sales estimate coming in at $132.33 million and the highest estimate coming in at $145.20 million. PetIQ posted sales of $115.07 million in the same quarter last year, which suggests a positive year over year growth rate of 20.8%. The business is expected to report its next quarterly earnings report on Tuesday, May 21st.
According to Zacks, analysts expect that PetIQ will report full year sales of $605.38 million for the current financial year, with estimates ranging from $600.50 million to $610.33 million. For the next year, analysts expect that the business will post sales of $692.11 million, with estimates ranging from $675.10 million to $711.04 million. Zacks’ sales averages are a mean average based on a survey of research analysts that follow PetIQ.
PetIQ (NASDAQ:PETQ) last released its quarterly earnings data on Monday, March 11th. The company reported $0.06 earnings per share for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.01). The business had revenue of $111.02 million during the quarter, compared to the consensus estimate of $98.72 million. PetIQ had a positive return on equity of 8.53% and a negative net margin of 0.15%.
In related news, insider Will Santana sold 20,000 shares of the business’s stock in a transaction dated Thursday, April 11th. The stock was sold at an average price of $31.06, for a total value of $621,200.00. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CFO John Newland sold 5,500 shares of the business’s stock in a transaction dated Wednesday, January 16th. The stock was sold at an average price of $29.00, for a total value of $159,500.00. The disclosure for this sale can be found here. Insiders sold 129,900 shares of company stock worth $3,780,716 over the last quarter. 45.26% of the stock is owned by company insiders.
Several large investors have recently bought and sold shares of PETQ. Macquarie Group Ltd. raised its position in PetIQ by 1,233.4% during the third quarter. Macquarie Group Ltd. now owns 51,228 shares of the company’s stock valued at $2,014,000 after purchasing an additional 47,386 shares during the period. JPMorgan Chase & Co. raised its position in PetIQ by 6,548.3% during the third quarter. JPMorgan Chase & Co. now owns 137,554 shares of the company’s stock valued at $5,407,000 after purchasing an additional 135,485 shares during the period. BCJ Capital Management LLC purchased a new stake in PetIQ during the fourth quarter valued at approximately $235,000. Portolan Capital Management LLC raised its position in PetIQ by 51.6% during the fourth quarter. Portolan Capital Management LLC now owns 93,290 shares of the company’s stock valued at $2,190,000 after purchasing an additional 31,768 shares during the period. Finally, Vanguard Group Inc raised its position in PetIQ by 30.3% during the third quarter. Vanguard Group Inc now owns 669,106 shares of the company’s stock valued at $26,303,000 after purchasing an additional 155,756 shares during the period. Institutional investors own 84.33% of the company’s stock.
NASDAQ PETQ opened at $31.56 on Tuesday. The stock has a market capitalization of $890.49 million, a PE ratio of 25.25, a price-to-earnings-growth ratio of 1.42 and a beta of 2.26. The company has a debt-to-equity ratio of 0.34, a current ratio of 3.24 and a quick ratio of 1.80. PetIQ has a twelve month low of $17.56 and a twelve month high of $43.93.
PetIQ Company Profile
PetIQ, Inc operates as a pet health and wellness company. It operates through two segments, Products and Services. It manufactures and distributes veterinarian services and veterinarian-grade pet products, including prescription (Rx) medications, over-the-counter (OTC) flea and tick preventatives, and health and wellness products for dogs and cats.
Read More: Marijuana Stocks Investing Considerations
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for PetIQ Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PetIQ and related companies with MarketBeat.com's FREE daily email newsletter.